Andira improves the efficacy of existing standard-of-care pharmaceuticals by applying synergistic amplification using a validated R&D platform. The resulting breakthrough innovations are uniquely positioned having a lesser barrier to market entry and pre-established global markets, being improved next-generation versions of standard-of-care agents already relied upon in the healthcare industry.

Andira’s lead product line for infection control is Matrix3™ Shield, an anti-infective medical device for advanced wound care. The underlying breakthrough technology is Matrix3™, a triple synergy silver-based antibiotic, shown to have over 1,000,000 times improved anti-bacterial efficacy versus conventional antimicrobial silver. Silver-based medical devices, wound dressings, surface coatings and topically applied drug products are used worldwide as a healthcare standard for infection control, despite medical research indicating these conventional silver products lack efficacy. Antimicrobial silver wound care products are a $1.28 billion market, with a high unmet need for new products with improved efficacy.

Silver-based Matrix3^TM represents a dramatic scientific breakthrough, being the world’s first broad-spectrum triple synergy antibiotic, positioned as a highly improved form of silver and suitable for all silver’s current medical uses.  Learn more about Matrix3™ and Andira’s portfolio of pharmaceutical technologies below.